


# Searching for better outcomes?

Illuminating molecular aberrations leads to improved outcomes.



#### Matched Cohort (n=534)

Median OS 1068 days

Median 3.2 treatments after profiling

#### Unmatched Cohort (n=493)

Median OS 646 days

Median 4.2 treatment after profiling

153 patients were excluded based on histology review or immature data.

Multi-platform molecular profiling of 1,180 patients increases median overall survival and influences treatment decision in 53% of cases. D. Spetzler, et al. *European Journal of Cancer*, September 2015, Volume 51, S44.

## Treatment decisions informed with tumor profiling improves clinical outcomes

As the foremost tumor profiling service, Caris Molecular Intelligence® helps oncologists illuminate better treatment plans proven to extend overall survival.



Our **Comprehensive Genomic Profiling PLUS (CGP+)** approach to assess DNA, RNA and Proteins reveals a molecular blueprint to guide more precise and individualized treatment decisions from among more than 60 FDA-approved oncology drugs. With results provided in 8-10 days, we'll help you find better answers when you need them most.

**A better foundation for precision oncology starts here.**

Learn more at [www.CarisMolecularIntelligence.com/outcomes](http://www.CarisMolecularIntelligence.com/outcomes).

© 2017 Caris Life Sciences. All rights reserved. TN3018



**CARIS**<sup>®</sup>  
LIFE SCIENCES